Free Trial
→ Federal Reserve Reveals Disturbing New Plan To Control Your Money (From Weiss Ratings) (Ad)tc pixel
NASDAQ:PHVS

Pharvaris Q3 2026 Earnings Date & Estimates

Pharvaris logo
$30.02 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$30.03 +0.01 (+0.03%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pharvaris is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026. The conference call is scheduled for November 12, 2026 at 12:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Conference Call Date
Conference Call
12:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Pharvaris in Q3 2026

Pharvaris is expected to post earnings of -$0.82 per share on revenue of $2.35 million. In the same quarter a year earlier Pharvaris reported -$0.70 per share. Pharvaris last reported on August 12, 2026, posting -$0.81 per share and missing the -$0.7467 consensus estimate. Pharvaris has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.82
Expected Revenue
$2.35 million
Prior-Year EPS
-$0.70

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.81 (Missed by -$0.0633)
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 Call

Pharvaris Q3 2026 Earnings FAQ

Pharvaris (NASDAQ:PHVS) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Pharvaris' Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 12:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Pharvaris to post earnings of -$0.82 per share for Q3 2026.

The consensus revenue estimate for Pharvaris is $2.35 million for Q3 2026.

Pharvaris Earnings Headlines

Pharvaris FY2028 Earnings Forecast Boosted by HC Wainwright
October 10, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31104393
Pharvaris' Rare Disease Drug Meets Primary, Secondary Goals in Phase 3 Trial
October 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/pharvaris-apos-rare-disease-drug-080950411.html
Did you grab your copy yet?
Bill Poulos's Top 10 Stocks to Buy This Quarter report is still available free, but not for long. Every quarter he swaps in a brand-new list, and once the new edition launches, this one disappears. Investors who want a current snapshot of his picks should grab a copy now and save it before the switch happens.tc pixel
October 14 at 1:00 AM  |  Profits Run (Ad)
Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet
October 9, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/phase-3-study-results-highlighting-deucrictibant-s-rapid-and-sustained-efficacy-in-treating-hae-attacks-published-in-the-lancet-1036610737
Pharvaris' Deucrictibant XR Cuts HAE Attack Rate By 83%; Plans NDA Filing In H1 2027
October 9, 2026  |  rttnews.comhttps://www.rttnews.com/3697775/pharvaris-deucrictibant-xr-cuts-hae-attack-rate-by-83-plans-nda-filing-in-h1-2027.aspx
Phase 3 Study Results Highlighting Deucrictibant's Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet
October 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/08/3377767/0/en/phase-3-study-results-highlighting-deucrictibant-s-rapid-and-sustained-efficacy-in-treating-hae-attacks-published-in-the-lancet.html
See More Pharvaris Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pharvaris? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pharvaris and other key companies, straight to your email.

About Pharvaris

Pharvaris (NASDAQ:PHVS) (NASDAQ:PHVS) is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE) and other diseases associated with bradykinin-mediated swelling. HAE is a rare genetic disorder that can cause recurring, potentially life-threatening attacks affecting areas such as the skin, gastrointestinal tract and airways.

The company’s lead program is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist formerly known as PHA121. Pharvaris is evaluating deucrictibant in immediate-release and extended-release formulations for the on-demand treatment and prevention of HAE attacks. The company’s development strategy is intended to provide convenient oral alternatives to injectable or infused therapies.

Pharvaris was founded by individuals with experience in HAE drug development and has operations in Europe and the United States. The company is advancing its pipeline through international clinical development programs and became a publicly traded company in 2021. Its headquarters are in Zug, Switzerland.

View Pharvaris Profile
Earnings Tools